There were many studies, articles and books Dr. Dressler and Dr. Ettinger used when writing The Dog Cancer Survival Guide. Here is a list of the most important references about chemotherapy.
Please note that in vivo and clinical use citations were included whenever possible. We have also included links to the papers, where available. Most of the papers are found on the National Institute of Health’s online library, PubMed.
Chemotherapy. Rodriquez CO, Rankin WV, Henry CJ, et al, in Henry CJ, Higginbotham ML (ed): Cancer Management in Small Animal Practice. Missouri. Saunders Elsevier 2010, p 101-121.
Managing Oncologic Emergencies. Dhaliwal RS, Wiebe VJ, Simonson E, et al, in Henry CJ, Higginbotham ML (ed): Cancer Management in Small Animal Practice. Missouri. Saunders Elsevier 2010, p 122-135
Cancer chemotherapy. Chun R, Garrett LD, Vail DM, in Withrow SJ, Vail DM (eds): Withrow & MacEwen’s Small Animal Clinical Oncology. Missouri, Saunders Elsevier, 2007, pp 163-192.
Impact of chemotherapeutic dose intensity and hematologic toxicity on first remission duration in dogs with lymphoma treated with a chemoradiotherapy protocol. Vaughan A, Johnson JL, Williams LE. J Vet Intern Med 21(6):1332-9, 2007.
Prophylactic trimethoprim-sulfadiazine during chemotherapy in dogs with lymphoma and osteosarcoma: a double-blind, placebo-controlled study. Chretin JD, Rassnick KM, Shaw NA, et al. J Vet Intern Med 21(1):141-8, 2007.
Risk factors for sterile hemorrhagic cystitis in dogs with lymphoma receiving cyclophosphamide with or without concurrent administration of furosemide: 216 cases (1990-1996). Charney SC, Bergman PJ, Hohenhaus AE, et al. J Am Vet Med Assoc.222(10):1388-93, 2003.
Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. Elmslie RE, Glawe P, Dow SW. J Vet Intern Med. 22(6):1373-9, 2008.
Safety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patient. FitzPatrick WM, Dervisis NG. Kitchell B. Veterinary and Comparative Oncology, 8: 273–282. 2010
Acute reactions in dogs treated with doxorubicin: increased frequency with the use of a generic formulation. Phillips BS, Kraegel SA, Simonson E, et al. J Vet Intern Med. 12(3):171-2, 1998.
Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. London CA, Malpas PB, Wood-Follis SL, et al. Clin Cancer Res. Jun 1;15(11):3856-65, 2009.
MOPP chemotherapy for treatment of resistant lymphoma in dogs: a retrospective study of 117 cases (1989-2000). Rassnick KM, Mauldin GE, Al-Sarraf R et al. J Vet Intern Med.16(5):576-8, 2002.
Efficacy of Maropitant in the Prevention of Delayed Vomiting Associated with Administration of Doxorubicin to Dogs. Rau S, Barber L, and Burgess K. J Vet Intern Med, 24: 1452–1457, 2010.
Tolerability of Metronomic Administration of Lomustine in Dogs with Cancer. Tripp C, Fidel J, Anderson C, et al. J Vet Intern Med, 25: 278–284, 2011.
There is a whole team of dog lovers behind Dog Cancer Vet and DogCancerBlog.com, and we’re here to help, because we understand what it’s like to deal with dog cancer. We work for Maui Media, the book publisher which includes paperback and digital copies of the best-selling animal health book Dog Cancer Survival Guide: Full Spectrum Treatments to Optimize Your Dog’s Life Quality and Longevity. This must-read book is available everywhere books are sold in paperback, and digital formats (iPad, Kindle, Nook). It is authored by our veterinarian bloggers Dr. Demian Dressler, and Dr. Susan Ettinger, DVM, ACVIM (Oncology).